890 / 1138
www.ckno.fr
Median follow up : 14.7 months
45 sunitinb , 61 sorafenib.
Two asymptomatic tumour haemorrhage
No skin toxicity, neurotoxicity or myelopathy
Local tumour control at 15 months : 98%
median pain score before SRS: 5 before and 0 after SRS.
Overall survival : 17.4 months spinal lesions
11.1 months cerebral lesions
(
P
=0.038).